How to buy Lexicon Pharmaceuticals stock | $4.39

Lexicon Pharmaceuticals, Inc is a biotechnology business based in the US. Lexicon Pharmaceuticals shares (LXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Lexicon Pharmaceuticals employs 78 staff and has a trailing 12-month revenue of around 0.00.

Lexicon Pharmaceuticals stock price (NASDAQ: LXRX)

Use our graph to track the performance of LXRX stocks over time.

Lexicon Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$4.39
52-week range	$1.03 - $9.43
50-day moving average	$4.44
200-day moving average	$5.65
Wall St. target price	$9.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.37

Buy Lexicon Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Lexicon Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lexicon Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lexicon Pharmaceuticals price performance over time

Historical closes compared with the close of $4.39 from 2021-05-28

1 week (2021-07-18)	N/A
1 month (2021-06-29)	-12.20%
3 months (2021-04-29)	-12.90%
6 months (2021-01-25)	N/A

1 year (2020-07-25)	N/A
2 years (2019-07-25)	N/A
3 years (2018-07-25)	N/A
5 years (2016-07-25)	N/A

Is Lexicon Pharmaceuticals under- or over-valued?

Valuing Lexicon Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lexicon Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Lexicon Pharmaceuticals's EBITDA

Lexicon Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $82.5 million.

The EBITDA is a measure of a Lexicon Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Lexicon Pharmaceuticals financials

Revenue TTM	$16 million
Gross profit TTM	$-129,055,000
Return on assets TTM	-29.2%
Return on equity TTM	-12.46%
Profit margin	-80.64%
Book value	$1.06
Market capitalisation	$512.6 million

TTM: trailing 12 months

Shorting Lexicon Pharmaceuticals shares

There are currently 4.4 million Lexicon Pharmaceuticals shares held short by investors – that's known as Lexicon Pharmaceuticals's "short interest". This figure is 24.4% up from 3.5 million last month.

There are a few different ways that this level of interest in shorting Lexicon Pharmaceuticals shares can be evaluated.

Lexicon Pharmaceuticals's "short interest ratio" (SIR)

Lexicon Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Lexicon Pharmaceuticals shares currently shorted divided by the average quantity of Lexicon Pharmaceuticals shares traded daily (recently around 1.2 million). Lexicon Pharmaceuticals's SIR currently stands at 3.79. In other words for every 100,000 Lexicon Pharmaceuticals shares traded daily on the market, roughly 3790 shares are currently held short.

However Lexicon Pharmaceuticals's short interest can also be evaluated against the total number of Lexicon Pharmaceuticals shares, or, against the total number of tradable Lexicon Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lexicon Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Lexicon Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0745% of the tradable shares (for every 100,000 tradable Lexicon Pharmaceuticals shares, roughly 75 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lexicon Pharmaceuticals.

Find out more about how you can short Lexicon Pharmaceuticals stock.

Lexicon Pharmaceuticals share dividends

We're not expecting Lexicon Pharmaceuticals to pay a dividend over the next 12 months.

Have Lexicon Pharmaceuticals's shares ever split?

Lexicon Pharmaceuticals's shares were split on a 1:7 basis on 20 May 2015. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lexicon Pharmaceuticals shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Lexicon Pharmaceuticals shares which in turn could have impacted Lexicon Pharmaceuticals's share price.

Lexicon Pharmaceuticals share price volatility

Over the last 12 months, Lexicon Pharmaceuticals's shares have ranged in value from as little as $1.03 up to $9.43. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexicon Pharmaceuticals's is 1.4788. This would suggest that Lexicon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Lexicon Pharmaceuticals overview

Lexicon Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. .

Frequently asked questions

What percentage of Lexicon Pharmaceuticals is owned by insiders or institutions?
Currently 4.178% of Lexicon Pharmaceuticals shares are held by insiders and 84.96% by institutions. How many people work for Lexicon Pharmaceuticals?
Latest data suggests 78 work at Lexicon Pharmaceuticals. When does the fiscal year end for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals's fiscal year ends in December. Where is Lexicon Pharmaceuticals based?
Lexicon Pharmaceuticals's address is: 8800 Technology Forest Place, The Woodlands, TX, United States, 77381-1160 What is Lexicon Pharmaceuticals's ISIN number?
Lexicon Pharmaceuticals's international securities identification number is: US5288723027 What is Lexicon Pharmaceuticals's CUSIP number?
Lexicon Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 528872104